Literature DB >> 16543919

The rationale for prophylactic cancer vaccines and need for a paradigm shift.

R E Sobol1.   

Abstract

This review summarizes clinical experience with infectious disease vaccines and data from animal tumor models that support a paradigm shift for cancer vaccines from therapeutic to prevention applications.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16543919     DOI： 10.1038/sj.cgt.7700950

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN： 0929-1903            Impact factor:   5.987


  5 in total

1.  Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer: a clinical phase I/II study.

Authors:  Anne Flörcken; Joachim Kopp; Antje van Lessen; Kamran Movassaghi; Anna Takvorian; Korinna Jöhrens; Markus Möbs; Constanze Schönemann; Birgit Sawitzki; Karl Egerer; Bernd Dörken; Antonio Pezzutto; Jörg Westermann
Journal:  Hum Vaccin Immunother       Date:  2013-03-04       Impact factor: 3.452

2.  Cancer vaccines: Looking to the future.

Authors:  Kavitha Yaddanapudi; Robert A Mitchell; John W Eaton
Journal:  Oncoimmunology       Date:  2013-03-01       Impact factor: 8.110

3.  IL-27 Improves Prophylactic Protection Provided by a Dead Tumor Cell Vaccine in a Mouse Melanoma Model.

Authors:  Kyle Seaver; Olena Kourko; Katrina Gee; Peter A Greer; Sameh Basta
Journal:  Front Immunol       Date:  2022-04-21       Impact factor: 8.786

4.  Cross-sectional and longitudinal analysis of cancer vaccination trials registered on the US Clinical Trials Database demonstrates paucity of immunological trial endpoints and decline in registration since 2008.

Authors:  Liangjian Lu; Haixi Yan; Vijay Shyam-Sundar; Tobias Janowitz
Journal:  Drug Des Devel Ther       Date:  2014-09-27       Impact factor: 4.162

Review 5.  Design of Outer Membrane Vesicles as Cancer Vaccines: A New Toolkit for Cancer Therapy.

Authors:  Yingxuan Zhang; Zheyan Fang; Ruizhen Li; Xiaotian Huang; Qiong Liu
Journal:  Cancers (Basel)       Date:  2019-09-06       Impact factor: 6.639
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.